Drug manufacturers of GLP-1 medications are facing lawsuits due to accusations of a possible association with non-arteritic anterior ischemic optic neuropathy, an eye condition that can result in irreversible vision loss. There are mixed findings in studies regarding this connection, prompting regulatory agencies to advise caution for patients noticing sudden vision alterations. Consultation with healthcare providers is essential for those affected.
